Recombinant Human CXCL13/BLC/BCA-1 Protein, CF 801-CX-025/CF from R&D Systems, a Bio-Techne Brand

Product Specs
ItemRecombinant Human CXCL13/BLC/BCA-1 Protein, CF
CompanyR&D Systems, a Bio-Techne Brand
Price $415.00Supplier Page View Company Product Page
Catalog Number801-CX-025/CF
Size25 ug (also 50 ug, 200 ug, 1 mg)
FormatLyophilized from a 0.2 µm filtered solution in Acetonitrile and TFA
Molecule NameCXCL13/BLC/BCA-1
NCBI Full Gene NameC-X-C motif chemokine ligand 13
NCBI Gene AliasesBCA-1, ANGIE2, BLR1L, SCYB13, ANGIE, BLC, BCA1
Purity>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
Molecular WeightObserved: 9 kDa, reducing conditions
Theoretical: 8.7 kDa
Source/Expression SystemE. coli-derived Recombinant Human CXCL13/BLC/BCA-1 Protein, CF
StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution
SpeciesHuman
Conjugate/TagUnconjugated
ApplicationsBioactivity

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956

Fax: 1 (612) 656-4400

(1) CXC chemokine ligand-13 promotes metastasis via CXCR5-dependent signaling pathway in non-small cell lung cancerJournal of cellular and molecular medicineOctober 1, 2021Chao CC, Lee WF, Wang SW, Chen PC, Yamamoto A, Chang TM, Weng SL, Liu JF.

(2) CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune responseProceedings of the National Academy of Sciences of the United States of AmericaNovember 17, 2020Biasci D, Smoragiewicz M, Connell CM, Wang Z, Gao Y, Thaventhiran JED, Basu B, Magiera L, Johnson TI, Bax L, et al.

(3) Group 3 innate lymphoid cells mediate early protective immunity against tuberculosisNatureJune 1, 2019Ardain A, Domingo-Gonzalez R, Das S, Kazer SW, Howard NC, Singh A, Ahmed M, Nhamoyebonde S, Rangel-Moreno J, Ogongo P, et al.

(4) Genomic analysis of benign prostatic hyperplasia implicates cellular re-landscaping in disease pathogenesisJCI insightMay 16, 2019Middleton LW, Shen Z, Varma S, Pollack AS, Gong X, Zhu S, Zhu C, Foley JW, Vennam S, Sweeney RT, et al.

(5) The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter TransformationCancer discoveryOctober 1, 2018Reiff SD, Mantel R, Smith LL, Greene JT, Muhowski EM, Fabian CA, Goettl VM, Tran M, Harrington BK, Rogers KA, et al.

(6) Role of CXCL13 and CCL20 in the recruitment of B cells to inflammatory foci in chronic arthritisArthritis research & therapyJune 7, 2018Armas-González E, Domínguez-Luis MJ, Díaz-Martín A, Arce-Franco M, Castro-Hernández J, Danelon G, Hernández-Hernández V, Bustabad-Reyes S, Cantabrana A, Uguccioni M, et al.

(7) BTK^Cys481Ser drives ibrutinib resistance via ERK1/2 and protects BTK^wild-type MYD88-mutated cells by a paracrine mechanismBloodMay 3, 2018Chen JG, Liu X, Munshi M, Xu L, Tsakmaklis N, Demos MG, Kofides A, Guerrera ML, Chan GG, Patterson CJ, et al.

(8) Regulatory and Helper Follicular T Cells and Antibody Avidity to Simian Immunodeficiency Virus Glycoprotein 120Journal of immunology (Baltimore, Md. : 1950)October 1, 2015Blackburn MJ, Zhong-Min M, Caccuri F, McKinnon K, Schifanella L, Guan Y, Gorini G, Venzon D, Fenizia C, Binello N, et al.

(9) Loss of circulating CD4 T cells with B cell helper function during chronic HIV infectionPLoS pathogensJanuary 1, 2014Boswell KL, Paris R, Boritz E, Ambrozak D, Yamamoto T, Darko S, Wloka K, Wheatley A, Narpala S, McDermott A, et al.

(10) Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitorsNatureJuly 26, 2012Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, et al.

(11) The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivoBloodFebruary 2, 2012Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, Keating MJ, O'Brien S, Chiorazzi N, Burger JA.

(12) IL8 and CXCL13 are potent chemokines for the recruitment of human neural precursor cells across brain endothelial cellsJournal of neuroimmunologyJune 1, 2010Weiss N, Deboux C, Chaverot N, Miller F, Baron-Van Evercooren A, Couraud PO, Cazaubon S.

(13) CCL21 overexpressed on lymphatic vessels drives thymic hyperplasia in myastheniaAnnals of neurologyOctober 1, 2009Berrih-Aknin S, Ruhlmann N, Bismuth J, Cizeron-Clairac G, Zelman E, Shachar I, Dartevelle P, de Rosbo NK, Le Panse R.

(20) Expression of functional CCR and CXCR chemokine receptors in podocytesJournal of immunology (Baltimore, Md. : 1950)June 15, 2002Huber TB, Reinhardt HC, Exner M, Burger JA, Kerjaschki D, Saleem MA, Pavenstädt H.

Recombinant Human CXCL13/BLC/BCA-1 Protein, CF from R&D Systems, a Bio-Techne Brand